You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Use of mobile phones in Norway and risk of intracranial tumours

Klaeboe, Larsa; Blaasaas, Karl Gerhardb; Tynes, Torea c

European Journal of Cancer Prevention:
doi: 10.1097/01.cej.0000203616.77183.4c
Research papers: Lifestyle and Environment
Abstract

To test the hypothesis that exposure to radio-frequency electromagnetic fields from mobile phones increases the incidence of gliomas, meningiomas and acoustic neuromas in adults. The incident cases were of patients aged 19–69 years who were diagnosed during 2001–2002 in Southern Norway. Population controls were selected and frequency-matched for age, sex, and residential area. Detailed information about mobile phone use was collected from 289 glioma (response rate 77%), 207 meningioma patients (71%), and 45 acoustic neuroma patients (68%) and from 358 (69%) controls. For regular mobile phone use, defined as use on average at least once a week or more for at least 6 months, the odds ratio was 0.6 (95% confidence interval 0.4–0.9) for gliomas, 0.8 (95% confidence interval 0.5–1.1) for meningiomas and 0.5 (95% confidence interval 0.2–1.0) for acoustic neuromas. Similar results were found with mobile phone use for 6 years or more for gliomas and acoustic neuromas. An exception was meningiomas, where the odds ratio was 1.2 (95% confidence interval 0.6–2.2). Furthermore, no increasing trend was observed for gliomas or acoustic neuromas by increasing duration of regular use, the time since first regular use or cumulative use of mobile phones. The results from the present study indicate that use of mobile phones is not associated with an increased risk of gliomas, meningiomas or acoustic neuromas.

Author Information

aThe Cancer Registry of Norway, Institute of Population-based Cancer Research

bNorwegian Armed Forces Joint Medical Services, Oslo

cNorwegian Radiation Protection Authority, Østerås, Norway

Correspondence and requests for reprints to Lars Klaeboe, MSc, The Cancer Registry of Norway, Institute of Population-Based Cancer Research, N-0310 Oslo, Norway

Tel: +47 22451300; fax: +47 22451370; e-mail: lars.klaeboe@kreftregisteret.no

Sponsorship: This study was supported by funding from the European Union Fifth Framework Program, ‘Quality of Life and Management of living Resources’ (contract QLK4-CT-1999-01563) and the International Union against Cancer (UICC). The UICC received funds for this purpose from the Mobile Manufacturers' Forum and GSM Association. Provision of funds to the INTERPHONE study investigators via the UICC was governed by agreements that guaranteed INTERPHONE's complete scientific independence. These agreements are publicly available at http://www.iarc.fr/ENG/Units/Rcad.html. No conflict of interest exists.

Received 26 October 2005 Accepted 11 January 2006

© 2007 Lippincott Williams & Wilkins, Inc.